Pilot Study Lp299v Supplementation in Chronic Heart Failure

Korábbi kezelés

• Patients who are receiving Vitamin K antagonists such as Coumadin or Warfarin
• Currently taking a Lactobacillus based probiotic as an outpatient at the time of enrollment

Más betegség

• Heart failure due to severe valve disease such as Aortic Stenosis, Mitral Regurgitation, or Mitral Stenosis
• Cancer besides non-melanoma skin carcinomas or localized prostate and breast cancer at the time of enrollment with life expectancy <1 year
• Lung disease such as Chronic Obstructive Pulmonary Disease (COPD), emphysema, or Pulmonary fibrosis
• Active inflammatory disease or infectious disease at the time of enrollment
• Current treatment (or use within the past 14 days) of steroids or anti-inflammatory treatments (excluding non-steroidal anti-inflammatory medications or steroids used solely for IV contrast dye allergy)
• Hepatic Failure (Child's Class B or C)
• Patients with Gastrointestinal (GI) tract illness such as short gut syndrome, inflammatory bowel disease, or an ileostomy, such that probiotic absorption would be altered
• Anticipated need for cardiac surgery during the projected study period for the subject
• Allergy to Lp299v probiotic supplement

Laborértékek

• Chronic Kidney Disease with eGFR ≤ 30 mL/min
• Neutropenia (Absolute Neutrophil Count (ANC) < 1800/mm3)

Egyéb

• Pregnancy
• Inability to give informed consent or follow the study protocol
• On antibiotics at the time of enrollment or within one month of enrollment
• Patients who are unable to walk on treadmill or use a bicycle to participate in exercise testing

• Age between 21-89 years old
• Clinical diagnosis of Congestive Heart Failure (CHF) in the six months prior to enrollment along with an echocardiogram documenting systolic dysfunction with ejection fraction ≤40%
• Clinical diagnosis of CHF in the six months prior to enrollment along with an echocardiogram documenting diastolic dysfunction with an ejection fraction ≥50%, and a H2FpEFF score of ≥6
• New York Heart Association (NYHA) Class II-IIID heart failure symptoms with either ischemic or non-ischemic etiology OR similar diagnosis with congestive heart failure (CHF) along with an echocardiogram documenting an LV ejection fraction of 50% or more with similar NYHA classification as those with LVEF of 40% or less
• Evidence of systemic inflammation at baseline (C-reactive protein ≥ 2 mg/L at the time of screening)